Roche, Prothena Enter Into Worldwide Collaboration to Co-Develop Antibodies ... Benzinga Roche (OTC: RHHBY) and Prothena Corporation plc (Nasdaq: PRTA), announced today that they have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal ... Roche and Prothena to Devlop Antibodies for Parkinson's Disease Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co ... Roche, Prothena ink potential $600 million deal for Parkinson's disease |
